Catalent Launches New Business Unit - The new unit aligns existing modified-release and medication-delivery businesses of the company. - BioPharm International

ADVERTISEMENT

Catalent Launches New Business Unit
The new unit aligns existing modified-release and medication-delivery businesses of the company.


The CDMO Catalent Pharma Solutions has created a new business unit, Advanced Delivery Technologies, which aligns the company’s existing modified-release and medication-delivery businesses, including biologics technologies and capabilities.

The new business unit will operate eight development and manufacturing facilities globally. These facilities include: those for fast-dissolve technologies at Swindon, United Kingdom; controlled-release technologies in Winchester, Kentucky, which is currently undergoing a major expansion, the recently expanded Schorndorf, Germany site; the advanced drug-development center in Somerset, New Jersey, the new biologics center of excellence in Madison, Wisconsin; advanced aseptic production in Woodstock, Illinois; and prefilled syringe facilities in Brussels, Belgium and Limoges, France.

The new business unit of Advanced Delivery Technologies complements existing business units for softgel technologies and development and Development and clinical services.

Barry Littlejohns has been named president of the new business unit. He has more than 25 years of experience in the drug-delivery industry spanning oral dose forms, parenteral delivery and biologics. “Our industry is facing tough challenges with increasingly difficult molecules, requiring more sophisticated development expertise, delivery technologies and supply capabilities to optimize bioavailability, therapeutic profiles and clinical outcomes,” he said in a company press release.“By bringing together talent and expertise from two proven teams, with our extensive intellectual property, technology and manufacturing platforms, we expect to partner with innovators around the world to deliver the most innovative, advanced and effective solutions to help bring more products to market faster and improve the efficacy of their treatments."

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines

Click here